Proposed Data Collections Submitted for Public Comment and Recommendations, 42413-42414 [E7-15020]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 148 / Thursday, August 2, 2007 / Notices
new public-private partnership will
develop a unified approach to realize an
effective, interoperable nationwide
health information system that supports
the health and well-being of the people
of this country. The input from this
public comment period will be used to
inform the plans for transitioning the
locus of activity from a Federal advisory
committee to a independent publicprivate partnership.
HHS and the AHIC are eager to hear
the thoughts of your organization with
respect to the AHIC successor entity. To
facilitate your participation in this
process, you are encouraged to provide
your comments organized by the
following concepts:
• Purpose and scope of the successor
entity
• Membership, including classes and
sectors
• Governing body and decisionmaking process
• Protections, incorporation,
management, and staffing
• Value of participation in the
successor entity for stakeholders
All comments in any format will be
accepted.
Comments should be received by
the Office of the National Coordinator
for Health Information Technology,
Department of Health and Human
Services, on or before 5 p.m. EST on
August 31, 2007.
DATES:
electronic responses are
preferred and may be recorded via the
Web site at https://www.hhs.gov/
healthit/commhnity/background/
AHICsuccessor.html or may be sent via
e-mail addressed to
AHICsuccessor@hhs.gov in the Office of
the National Coordinator for Health
Information Technology, Department of
Health and Human Services. Please
include ‘‘AHIC Successor White Paper
Comments’’ in the subject line.
Paper-based responses will also be
accepted. Please send to: Office of the
National Coordinator for Health
Information Technology, Department of
Health and Human Services, Attention:
AHIC Successor White Paper
Comments, Mary C. Switzer Building,
330 C Street, SW., Room 4080,
Washington, DC 20201, or fax to (202)
690–6079, Attention: AHIC Successor
White Paper Comments.
mstockstill on PROD1PC66 with NOTICES
ADDRESSES:
Visit https://
www.hhs.gov/healthit/community/
background/AHICsuccessor.html.
FOR FURTHER INFORMATION:
VerDate Aug<31>2005
17:42 Aug 01, 2007
Jkt 211001
Dated: July 27, 2007.
Michelle Murray,
Office of Programs and Coordination, Office
of the National Coordinator for Health
Information Technology.
[FR Doc. 07–3768 Filed 8–1–07; 8:45 am]
BILLING CODE 4150–24–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60–Day–07–07BN]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–5960 and
send comments to Maryam I. Daneshvar,
CDC Acting Reports Clearance Officer,
1600 Clifton Road, MS–D74, Atlanta,
GA 30333 or send an e-mail to
omb@cdc.gov.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
Pilot Project to Estimate the Incidence
of Hepatitis C Virus (HCV) Infection
Among Young Injection Drug Users
(IDUs) Using Serial Cross-Sectional
Seroprevalence Surveys—New—
National Center for HIV, Hepatitis, STD,
and TB Prevention (NCHHSTP), Centers
for Disease Control and Prevention
(CDC).
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
42413
Background and Brief Description
Hepatitis C is the most prevalent
bloodborne infection in the United
States; approximately 3.2 million
persons are chronically infected with
HCV. National recommendations for
prevention and control of HCV infection
emphasize primary prevention activities
to reduce the risk of HCV transmission.
Identifying and reaching persons at risk
for HCV infection to provide riskreduction counseling is thus critical to
prevent infection. Currently the Centers
for Disease Control and Prevention
(CDC) monitors the national incidence
of acute hepatitis C through passive
surveillance of acute, symptomatic cases
of laboratory confirmed hepatitis C.
However, only a minority of people
with acute infection have symptoms at
all (<25%) and passive surveillance
only captures a small fraction of acutely
infected people, i.e., those who have
symptoms and receive medical attention
and appropriate laboratory testing
during the acute phase of the disease.
Injection drug users (IDUs), who are the
primary risk group for acute hepatitis C
(70% of identified acute cases), have
additional barriers to health care access
and/or utilization resulting in the
potential for a further underestimation
of overall incidence. Thus, it is
necessary to consider strategies other
than passive surveillance for incidence
monitoring. One such strategy is to
conduct Serial Cross-Sectional
Seroprevalence Surveys (SCSS) among
populations at increased risk of
infection such as IDUs.
For the proposed pilot project,
funding will be awarded to selected U.S.
sites that will develop and test different
methods to recruit a sample of young
IDUs that is most representative of the
population of young IDUs at risk for
HCV infection. These sampling methods
will be compared and contrasted to
identify a methodology to be used in
ongoing SCSSs among young IDUs.
Better methods of identification of
persons at risk will enhance current
surveillance efforts to monitor the
incidence of HCV infection which in
turn are the best means to direct and
assess primary prevention strategies,
determine new transmission patterns,
and identify and control outbreaks.
Moreover, methods developed in this
study can be used in other areas to
gather representative data on incidence
of acute disease and the burden of
disease caused by HCV infection.
In addition, instruments for collecting
behavioral/risk factor data from IDUs
will be developed and pilot tested. It is
estimated that data will be collected
over 15 months from a total of 2000
E:\FR\FM\02AUN1.SGM
02AUN1
42414
Federal Register / Vol. 72, No. 148 / Thursday, August 2, 2007 / Notices
guide the development of prevention
and control strategies.
Participation in the data collection is
voluntary and there is no cost to
respondents to participate in the survey
other than their time.
beliefs about HCV infection. The utility
of using HCV nucleic acid testing
(NAT), antigen-antibody testing and
other testing modalities to identify seroincident (window period) infections
will also be assessed. Knowledge of
factors associated with acquiring
hepatitis C virus infection is essential to
respondents. The total annual burden
for this project is expected to be 1600
hours. The information to be collected
includes demographic data, risk factors
for HCV infection, missed opportunities
for prevention (including hepatitis A
and B vaccination), access to medical
care, and knowledge, attitudes, and
ESTIMATED ANNUALIZED BURDEN HOURS
Respondents
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total burden
(in hours)
Young injection drug users ..............................................................................
1600
1
1
1600
Dated: July 27, 2007.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E7–15020 Filed 8–1–07; 8:45 am]
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Proposed Project
[60 Day-07–0020]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–5960 and
send comments to Maryam I. Daneshvar,
CDC Acting Reports Clearance Officer,
1600 Clifton Road, MS–D74, Atlanta,
GA 30333 or send an email to
omb@cdc.gov.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
Coal Workers’ X-ray Surveillance
Program (CWXSP) OMB # 0920–0020—
Extension—The National Institute for
Occupational Safety and Health
(NIOSH), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
The CWXSP is a federally mandated
program under the Federal Mine Safety
and Health Act of 1977, Public Law 95–
164. The Act provides the regulatory
authority for the administration of the
CWXSP, a surveillance program to
protect the health and safety of
underground coal miners. This Program
requires the gathering of demographic
and logistical information from coal
mine operators, participating miners,
participating x-ray facilities, and
participating physicians. The
Appalachian Laboratory for
Occupational Safety and Health
(ALOSH), located in Morgantown, WV,
is charged with administration of this
Program. Over the past two years,
participation in the CWXSP has
increased, which is reflected in this
submission for renewal. Based on an
average of 5,000 x-rays coming into the
Program per year (each x-ray receives
two readings), and using the average
hourly wage rates taken from the Bureau
of Labor Statistics, National
Occupational Employment and Wage
Estimates, the total annualized burden
hours is 2,329. Physicians (B Readers)
will fill out forms regarding their
interpretations of the x-rays. Based on
prior practice it takes the physician
approximately 3 minutes per form.
Physicians taking the B Reader
Examination are asked to complete a
registration form which takes
approximately 10 minutes to complete.
There are approximately 300 physicians
each year taking the certification exam.
Miners participating in the CWXSP
must fill out the Miner Identification
Document which requires
approximately 20 minutes. There are
about 5,000 miners participating in the
CWXSP Program. Mine operators are
required to file a Mine x-ray Plan with
NIOSH approximately every 3 years. It
takes the mine operator approximately
30 minutes to complete this form.
Approximately 200 mine operators have
x-ray plans that are due for renewal
each year. An x-ray facility that applies
to be a NIOSH-approved facility for
providing miners x-rays must complete
an approval packet. The forms
associated with this approval process
require approximately 30 minutes for
completion. There are approximately 25
x-ray facilities each year seeking
approval into the CWXSP Program.
Overall, there will be no costs to study
participants.
mstockstill on PROD1PC66 with NOTICES
ESTIMATES OF ANNUALIZED BURDEN HOURS
Number of
respondents
Respondents
Physicians/interpretations ................................................................................
VerDate Aug<31>2005
17:42 Aug 01, 2007
Jkt 211001
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
Average
burden/response
(in hrs.)
Number of
responses/
respondent
10,000
E:\FR\FM\02AUN1.SGM
1
02AUN1
3/60
Total burden
(in hrs.)
500
]]>Agencies
[Federal Register Volume 72, Number 148 (Thursday, August 2, 2007)]
[Notices]
[Pages 42413-42414]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-15020]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60-Day-07-07BN]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call 404-639-5960
and send comments to Maryam I. Daneshvar, CDC Acting Reports Clearance
Officer, 1600 Clifton Road, MS-D74, Atlanta, GA 30333 or send an e-mail
to omb@cdc.gov.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology. Written comments should be received
within 60 days of this notice.
Proposed Project
Pilot Project to Estimate the Incidence of Hepatitis C Virus (HCV)
Infection Among Young Injection Drug Users (IDUs) Using Serial Cross-
Sectional Seroprevalence Surveys--New--National Center for HIV,
Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
Hepatitis C is the most prevalent bloodborne infection in the
United States; approximately 3.2 million persons are chronically
infected with HCV. National recommendations for prevention and control
of HCV infection emphasize primary prevention activities to reduce the
risk of HCV transmission. Identifying and reaching persons at risk for
HCV infection to provide risk-reduction counseling is thus critical to
prevent infection. Currently the Centers for Disease Control and
Prevention (CDC) monitors the national incidence of acute hepatitis C
through passive surveillance of acute, symptomatic cases of laboratory
confirmed hepatitis C. However, only a minority of people with acute
infection have symptoms at all (<25%) and passive surveillance only
captures a small fraction of acutely infected people, i.e., those who
have symptoms and receive medical attention and appropriate laboratory
testing during the acute phase of the disease. Injection drug users
(IDUs), who are the primary risk group for acute hepatitis C (70% of
identified acute cases), have additional barriers to health care access
and/or utilization resulting in the potential for a further
underestimation of overall incidence. Thus, it is necessary to consider
strategies other than passive surveillance for incidence monitoring.
One such strategy is to conduct Serial Cross-Sectional Seroprevalence
Surveys (SCSS) among populations at increased risk of infection such as
IDUs.
For the proposed pilot project, funding will be awarded to selected
U.S. sites that will develop and test different methods to recruit a
sample of young IDUs that is most representative of the population of
young IDUs at risk for HCV infection. These sampling methods will be
compared and contrasted to identify a methodology to be used in ongoing
SCSSs among young IDUs. Better methods of identification of persons at
risk will enhance current surveillance efforts to monitor the incidence
of HCV infection which in turn are the best means to direct and assess
primary prevention strategies, determine new transmission patterns, and
identify and control outbreaks. Moreover, methods developed in this
study can be used in other areas to gather representative data on
incidence of acute disease and the burden of disease caused by HCV
infection.
In addition, instruments for collecting behavioral/risk factor data
from IDUs will be developed and pilot tested. It is estimated that data
will be collected over 15 months from a total of 2000
[[Page 42414]]
respondents. The total annual burden for this project is expected to be
1600 hours. The information to be collected includes demographic data,
risk factors for HCV infection, missed opportunities for prevention
(including hepatitis A and B vaccination), access to medical care, and
knowledge, attitudes, and beliefs about HCV infection. The utility of
using HCV nucleic acid testing (NAT), antigen-antibody testing and
other testing modalities to identify sero-incident (window period)
infections will also be assessed. Knowledge of factors associated with
acquiring hepatitis C virus infection is essential to guide the
development of prevention and control strategies.
Participation in the data collection is voluntary and there is no
cost to respondents to participate in the survey other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Respondents Number of responses per per response Total burden
respondents respondent (in hours) (in hours)
----------------------------------------------------------------------------------------------------------------
Young injection drug users.................. 1600 1 1 1600
----------------------------------------------------------------------------------------------------------------
Dated: July 27, 2007.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. E7-15020 Filed 8-1-07; 8:45 am]
BILLING CODE 4163-18-P
